Compare Cassava Sciences Inc (FLNA) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs CarMax, Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while CarMax, Inc trades at $52.79 (market cap $7.64B). The key difference: CarMax, Inc is far larger — about 193.9× Cassava Sciences Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and CarMax, Inc for 49 Days on average.
| FLNA | KMX | |
|---|---|---|
Market Cap | $39.40M | $7.64B |
Volume | 759,018 | 3,610,116 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $64.22 |
52-Week Low | $0.68 | $30.88 |
Typical Hold Time | 37 Days | 49 Days |
Enterprise Value | -$43.28M | $25.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
CarMax (KMX) trades at $52.82, down 0.86% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $1.16 beating estimates by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show a P/E of 25.37 and P/S of 0.28, while profitability remains modest with 1.06% net margin. Recent news highlights the company's 'Shift into GEAR' turnaround strategy showing early success.
KMX presents a mixed outlook with improving operational performance offset by high debt levels and competitive pressures. The consensus price target of $58.89 suggests 11% upside potential, but analysts remain cautious with 62% hold ratings. Key risks include cyclical auto market exposure and interest rate sensitivity, while catalysts include continued execution of the turnaround strategy and potential share buybacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
